pazopanib hydrochloride

FDA Drug Profile — pazopanib, VOTRIENT

pazopanib hydrochloride is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand names including pazopanib, VOTRIENT. Available dosage form: tablet, film coated.

Drug details

Generic Name
pazopanib hydrochloride
Brand Names
pazopanib, VOTRIENT
Application Number
ANDA219922
Sponsor
Torrent Pharmaceuticals Limited
NDC Codes
5
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
PAZOPANIB HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). ( 1.1 ) advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use: The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma Pazopanib tablets are indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use: The efficacy of pazopanib tablets for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.